Clinical Data Sanofi says drug for rare disease AATD tops standard care PharmaphorumAfter a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx.Rare DiseaseRead full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum After a phase 2 readout, Sanofi is charting a route to market for AATD therapy efdoralprin alfa, acquired as part of its $2.2bn takeover of Inhibrx. Rare Disease Read full story Post navigation Previous: VERTANICAL’s VER-01 gains FDA breakthrough status for low back painNext: European study shows inequality in access to new medicines Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026